Treatment Clinical Trials for Intraocular Melanoma

Clinical trials are research studies that involve people. The clinical trials on this list are for intraocular melanoma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 25
  • Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

    To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
    Location: 18 locations

  • A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors

    This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and / or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
    Location: 6 locations

  • Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

    RPL-001-16 is a Phase 1 / 2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and / or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
    Location: 6 locations

  • Study in Subjects With Small Primary Choroidal Melanoma

    The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
    Location: 4 locations

  • Study of IDE196 in Patients With Solid Tumors Harboring GNAQ / 11 Mutations or PRKC Fusions

    This is a Phase 1 / 2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ / 11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.
    Location: 3 locations

  • Selumetinib Sulfate in Treating Patients with Uveal Melanoma or GNAQ / GNA11 Mutated Melanoma That Is Metastatic or Cannot Be Removed by Surgery

    This phase Ib trial studies the side effects and best dose of selumetinib sulfate in treating patients with uveal melanoma or GNAQ / GNA11 mutated melanoma that has spread from the primary site to other places in the body or cannot be removed by surgery. Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Modified Virus VSV-IFNbetaTYRP1 in Treating Patients with Stage III-IV Melanoma

    This phase I trial studies the side effects and best dose of a modified virus called VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma. The vesicular stomatitis virus (VSV) has been altered to include two extra genes: human interferon beta (hIFNbeta), which may protect normal healthy cells from becoming infected with the virus, and TYRP1, which is expressed mainly in melanocytes (specialized skin cell that produces the protective skin-darkening pigment melanin) and melanoma tumor cells, and may trigger a strong immune response to kill the melanoma tumor cells.
    Location: 2 locations

  • Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

    Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy. The investigators will explore this synergy with a feasibility study of 26 patients with uveal melanoma and hepatic metastases who will receive SirSpheres Yttrium-90 selective internal hepatic radiation followed by immunotherapy with the combination of ipilimumab and nivolumab.
    Location: 2 locations

  • Pegargiminase, Nivolumab and Ipilimumab in Treating Patients with Advanced or Unresectable Uveal Melanoma

    This phase I trial studies the side effects of pegargiminase, nivolumab and ipilimumab in treating patients with uveal melanoma that has spread to other places in the body (advanced) or cannot be removed by surgery (unresectable). Pegargiminase may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pegargiminase, nivolumab and ipilimumab may be better compared to immunotherapy alone.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients with Uveal Melanoma

    This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

    The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
    Location: Hackensack University Medical Center, Hackensack, New Jersey

  • A Vaccine (6MHP) with or without CDX-1127 for the Treatment of Stage IIB-IV Melanoma

    This phase I / II trial studies the side effects and how well a vaccine (6MHP) with or without CDX-1127 work for the treatment of stage IIB-IV melanoma. Vaccines, such as 6MHP, may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as CDX-1127, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial is being done to see what effects 6MHP alone and in combination with CDX-1127 have on changes in the immune system.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Ipilimumab and Nivolumab with Immunoembolization in Treating Patients with Metastatic Uveal Melanoma in the Liver

    This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes, and Aldesleukin in Treating Participants with Metastatic Uveal Melanoma

    This phase II trial studies how well cyclophosphamide, fludarabine, tumor infiltrating lymphocytes, and aldesleukin work in treating participants with uveal melanoma that has spread to other places in the body. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Tumor infiltrating lymphocytes may be an effective treatment for uveal melanoma. Aldesleukin may stimulate white blood cells to kill uveal melanoma cells. Giving cyclophosphamide, fludarabine, tumor infiltrating lymphocytes, and aldesleukin may kill more tumor cells.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • A Study of PLX2853 in Advanced Malignancies.

    The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Autologous CD8+ SLC45A2-Specific T Lymphocytes with Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Participants with Metastatic Uveal Melanoma

    This phase Ib trial studies the side effects and best dose of autologous CD8 positive (+) SLC45A2-specific T lymphocytes when given together with cyclophosphamide, aldesleukin, and ipilimumab, and to see how well they work in treating participants with uveal melanoma that has spread to other places in the body. To make specialized CD8+ T cells, researchers separate out T cells collected from participant blood and treat them so they are able to target melanoma cells. The blood cells are then given back to the participant. This is known as "adoptive T cell transfer" or "adoptive T cell therapy." Drugs used in chemotherapy, such as cyclophosphamide, may work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Biological therapies, such as aldesleukin, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving autologous CD8+ SLC45A2-specific T lymphocytes together with cyclophosphamide, aldesleukin, and ipilimumab may work better in treating participants with metastatic uveal melanoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Intravenous and Intrathecal Nivolumab in Treating Patients with Leptomeningeal Disease

    This phase I / Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Nivolumab with or without Ipilimumab or Relatlimab before Surgery in Treating Patients with Stage IIIB-IV Melanoma That Can Be Removed by Surgery

    This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, and relatlimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab alone or in combination with ipilimumab or relatlimab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: M D Anderson Cancer Center, Houston, Texas

  • 6MHP Vaccine and Ipilimumab in Treating Patients with Stage IIA-IV Melanoma

    This phase I / II trial studies the side effects of 6 melanoma helper peptide vaccine (6MHP) and ipilimumab and to see how well they work in treating patients with stage IIA-IV melanoma. Vaccines made from peptides, such as 6MHP vaccine, may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving 6MHP vaccine and ipilimumab works better in treating patients with melanoma.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Dabrafenib Mesylate, Trametinib, and 6 Melanoma Helper Peptide Vaccine in Treating Patients with Stage IIIB-IV Melanoma

    This phase I / II trial studies the side effects and how well dabrafenib mesylate, trametinib, and 6 melanoma helper peptide vaccine work in treating patients with stage IIIB-IV melanoma. Dabrafenib mesylate and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines, such as 6 melanoma helper peptide vaccine, made from peptides derived from melanoma proteins, may help the body build an effective immune response to kill tumor cells that express melanoma-specific antigens. Giving dabrafenib, trametinib, and 6 melanoma helper peptide vaccine may work better in treating patients with melanoma.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

    This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma

    This randomized phase II trial studies how well therapeutic tumor infiltrating lymphocytes and high-dose aldesleukin with or without autologous dendritic cells work in treating patients with melanoma that has spread to other areas of the body. Vaccines made from a person's tumor cells and special blood cells (dendritic cells) may help the body build an effective immune response to kill tumor cells. Aldesleukin may stimulate the white blood cells to kill tumor cells. It is not yet known whether therapeutic tumor infiltrating lymphocytes and high-dose aldesleukin are more effective when given together with or without dendritic cells in shrinking or slowing the growth of melanoma. The clinical benefits of receiving tumor infiltrating lymphocytes (TIL) in combination with the B-Raf proto-oncogene, serine / threonine kinase (BRAF) inhibitor will be studied, in patients who have progressive disease (PD) with using the BRAF inhibitor prior to TIL treatment. Leptomeningeal disease (LMD) is unfortunately a common development in patients with melanoma, with an extremely poor prognosis, translating into an overall survival of only weeks. With the novel approach of combining intrathecal TILs and intrathecal interleukin (IL)-2, researchers hope to induce long term disease stabilization or remission of LMD.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Vorinostat for the Treatment of Class 2 High Risk Uveal Melanoma

    This early phase I trial studies how well vorinostat works in treating patients with high risk uveal (eye) melanoma. Researchers are finding that the cells in uveal melanomas are mostly divided into two types: class 1 and class 2. The class 2 cells tend to have a higher chance of moving to other organs in the body, while the class 1 cells mostly stay in the eye. Vorinostat may be able to change class 2 cells into the less aggressive class 1-type cells by "turning on" the genes in the cell that suppresses tumors.
    Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

  • Ulixertinib in Treating Patients with Stage IV Uveal Melanoma

    This phase II trial studies the side effects of ulixertinib and how well it works in treating patients with stage IV uveal melanoma. Ulixertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: See Clinical Trials.gov

  • Vorinostat in Treating Patients with Metastatic Melanoma of the Eye

    This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: See Clinical Trials.gov